Amgen, Inc. (AMGN)
442.81
+4.69
(+1.07%)
USD |
NASDAQ |
Sep 02, 16:00
440.54
-2.27
(-0.51%)
After-Hours: 17:49
Amgen Research and Development Expense (TTM) : 7.638B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.638B |
| March 31, 2026 | 7.514B |
| December 31, 2025 | 7.281B |
| September 30, 2025 | 6.828B |
| June 30, 2025 | 6.378B |
| March 31, 2025 | 6.081B |
| December 31, 2024 | 5.938B |
| September 30, 2024 | 5.762B |
| June 30, 2024 | 5.391B |
| March 31, 2024 | 5.057B |
| December 31, 2023 | 4.772B |
| September 30, 2023 | 4.574B |
| June 30, 2023 | 4.607B |
| March 31, 2023 | 4.533B |
| December 31, 2022 | 4.434B |
| September 30, 2022 | 4.458B |
| June 30, 2022 | 4.768B |
| March 31, 2022 | 4.811B |
| December 31, 2021 | 4.819B |
| September 30, 2021 | 4.70B |
| June 30, 2021 | 4.34B |
| March 31, 2021 | 4.222B |
| December 31, 2020 | 4.207B |
| September 30, 2020 | 4.29B |
| June 30, 2020 | 4.229B |
| Date | Value |
|---|---|
| March 31, 2020 | 4.189B |
| December 31, 2019 | 4.116B |
| September 30, 2019 | 3.986B |
| June 30, 2019 | 3.911B |
| March 31, 2019 | 3.856B |
| December 31, 2018 | 3.737B |
| September 30, 2018 | 3.598B |
| June 30, 2018 | 3.549B |
| March 31, 2018 | 3.553B |
| December 31, 2017 | 3.562B |
| September 30, 2017 | 3.597B |
| June 30, 2017 | 3.71B |
| March 31, 2017 | 3.737B |
| December 31, 2016 | 3.84B |
| September 30, 2016 | 3.839B |
| June 30, 2016 | 3.955B |
| March 31, 2016 | 4.001B |
| December 31, 2015 | 4.006B |
| September 30, 2015 | 4.129B |
| June 30, 2015 | 4.026B |
| March 31, 2015 | 4.098B |
| December 31, 2014 | 4.248B |
| September 30, 2014 | 4.297B |
| June 30, 2014 | 4.283B |
| March 31, 2014 | 4.232B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.943B |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| AbbVie, Inc. | 9.714B |
| Biogen, Inc. | 1.736B |
| Vertex Pharmaceuticals, Inc. | 3.907B |